Delivery Order SPE2DB22D3016-SPE2DB25FAZT7
Award Date 6/18/25
Potential Completion Date 6/20/25
Potential Value $10K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $4,734.27 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by June 3, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a $12,446.64 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a prescription medication used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $3,578.79 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) on September 9, 2025, with completion expected by September 10, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order valued at $10,006.04 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with completion expected by July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,835.46 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $9,334.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price, non-set-aside contract was awarded on August 20, 2025, with an ultimate completion date of August 21, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $35,073.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 30, 2025, with performance completion due July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a $3,231.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit of use packaging), with an ultimate completion date of July 31, 2025. This non-set-aside contract was awarded on July 30, 2025, and will be performed at the company's Corporate Office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit of use packaging) with an ultimate completion date of September 8, 2025. This is a firm fixed price, non-set-aside competitively awarded delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be...
- The Defense Logistics Agency (DLA) awarded a $56,308.41 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) on July 8, 2025, with an ultimate completion date of July 9, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical...